PLAU and pancreatic neoplasm: Finally, we assessed the effects of uPA inhibition on tumour growth and metastasis using the uPA inhibitor BB230F at 3mg (U3) and 10mg (U10)/kg body weight alongside the standard of care drug gemcitabine in an early intervention orthotopic xenograft mouse model of pancreatic cancer (Figure 14A).